Z Gastroenterol 2013; 51(05): 440-443
DOI: 10.1055/s-0033-1335012
Kasuistik
© Georg Thieme Verlag KG Stuttgart · New York

Manifestation of an Abdominal Immune Reconstitution Inflammatory Syndrome Associated with a Nontuberculous Mycobacterial Infection – A Case Report

Manifestation eines abdominellen inflammatorischen Immunrekonstitutions-Syndroms assoziiert mit einer nicht tuberkulösen Mykobakterien-Infektion – Ein Fallbericht
B. Meier
1   Gastroenterologie, Klinikum Ludwigsburg
,
A. Schmidt
1   Gastroenterologie, Klinikum Ludwigsburg
,
G. Kalmar
1   Gastroenterologie, Klinikum Ludwigsburg
,
K. Caca
1   Gastroenterologie, Klinikum Ludwigsburg
,
D. Wagner
2   Infektiologie und Reisemedizin, Universitätsklinikum Freiburg
› Author Affiliations
Further Information

Publication History

12 January 2013

20 January 2013

Publication Date:
16 May 2013 (online)

Abstract

Immune reconstitution inflammatory syndrome (IRIS) is an inflammatory reaction in HIV-infected patients after initiation of antiretroviral therapy. It results from restored immunity to specific infectious or non-infectious antigens. We describe the case of a 47-year-old female patient who presented with an unspecific painful pressure in the abdomen and weight loss that was diagnosed as intra-abdominal (unmasking) IRIS due to nontuberculous mycobacterial infection (Mycobacterium avium complex). Antiretroviral therapy had been initiated six months earlier when pneumocystis pneumonia led to the diagnosis of HIV infection with a viral load of 123 000 copies/ml and a CD 4 cell count of 6/µl. Although IRIS is a known complication after initiation of antiretroviral therapy in HIV-infected patients this case with a rare site of manifestation and symptoms that are common in all day gastroenterological clinic highlights a differential diagnosis that requires a high index of suspicion and the need for the careful use of diagnostic tools.

Zusammenfassung

Das immunrekonstitutionelle inflammatorische Syndrom (IRIS) ist durch eine entzündliche Immunreaktion charakterisiert, welche nach Einleitung einer antiretroviralen Therapie bei HIV-Patienten auftritt. Es resultiert aus der zurückgewonnenen Immunität gegenüber Infektionserregern oder nichtinfektiöser Antigene. Wir beschreiben den Fall einer 47-jährigen Patientin, die sich mit unspezifischen drückenden Bauchschmerzen und Gewichtsverlust vorstellte, die Folgen eines intraabdominellen (demaskierenden) IRIS aufgrund einer nicht tuberkulösen Mykobakteriose (Mycobacterium avium complex) waren. Sechs Monate zuvor war eine antiretrovirale Therapie eingeleitet worden, nachdem bei der Patientin im Rahmen einer Pneumozystis-Pneumonie eine HIV-Infektion (Stadium C3, Viruslast 123 000 Kopien/ml, CD-4 Zellzahl 6/µl) erstdiagnostiziert worden war. Obwohl das IRIS eine bekannte Komplikation nach Einleitung der antiretroviralen Therapie bei HIV-Patienten ist, beleuchtet dieser Fall mit einer seltenen intraabdominellen Manifestation und Beschwerden, die wir tagtäglich in unserer gastroenterologischen Klinik erleben, eine Differenzialdiagnose, an die gedacht werden muss und die eine sorgfältige Wahl der diagnostischen Verfahren erfordert.

 
  • References

  • 1 Elliott JH, Vohith K, Saramony S. et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 2009; 200: 1736-1745
  • 2 Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 2011; 9: 415-430
  • 3 Huis in 't Veld D, Sun HY, Hung CC. et al. The immune reconstitution inflammatory syndrome related to HIV co-infections: a review. Eur J Clin Microbiol Infect Dis 2012; 31: 919-927
  • 4 Novak RM, Richardson JT, Buchacz K. et al. Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS 2012; 26: 721-730
  • 5 Falkinham III JO. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002; 23: 529-551
  • 6 Hojo M, Iikura M, Hirano S. et al. Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long-term inhaled corticosteroid therapy. Respirology 2012; 17: 185-190
  • 7 Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002; 20: 581-620
  • 8 Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000; 11: 321-333
  • 9 Kaplan JE, Benson C, Holmes KH. et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1-207
  • 10 Nightingale SD, Byrd LT, Southern PM. et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082-1085
  • 11 Griffith DE, Aksamit T, Brown-Elliott BA. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416
  • 12 Riddell J, Kaul DR, Karakousis PC. et al. Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. J Transl Med 2007; 5: 50
  • 13 Phillips P, Bonner S, Gataric N. et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41: 1483-1497
  • 14 French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009; 48: 101-107
  • 15 Lange CG, Woolley IJ, Brodt RH. Disseminated Mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?. Drugs 2004; 64: 679-692
  • 16 Therapie und Prophylaxe opportunistischer Infektionen bei HIV-infizierten Patienten. 2011 www.awmf.org
  • 17 Desimone JrJA, Babinchak TJ, Kaulback KR. et al. Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. AIDS Patient Care STDS 2003; 17: 617-622
  • 18 Benson CA, Williams PL, Currier JS. et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37: 1234-1243
  • 19 Havlir D, Torriani F, Dube M. Uveitis associated with rifabutin prophylaxis. Ann Intern Med 1994; 121: 510-512
  • 20 Siegal FP, Eilbott D, Burger H. et al. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS 1990; 4: 433-441
  • 21 Meintjes G, Wilkinson RJ, Morroni C. et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-2390
  • 22 Jehle AW, Khanna N, Sigle JP. et al. Acute renal failure on immune reconstitution in an HIV-positive patient with miliary tuberculosis. Clin Infect Dis 2004; 38: e32-e35
  • 23 Goldsack NR, Allen S, Lipman MC. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect 2003; 79: 337-338
  • 24 Lawn SD, Bicanic TA, Macallan DC. Pyomyositis and cutaneous abscesses due to Mycobacterium avium: an immune reconstitution manifestation in a patient with AIDS. Clin Infect Dis 2004; 38: 461-463